Soleno Therapeutics Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome

Reuters01-05

<a href="https://laohu8.com/S/SLNO">Soleno Therapeutics</a> Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome

Soleno Therapeutics Inc. has announced the publication of results from a pivotal clinical study evaluating VYKAT™ XR (diazoxide choline extended-release tablets) in the treatment of hyperphagia in individuals with Prader-Willi syndrome $(PWS)$. The results, now published in the Journal of Clinical Endocrinology and Metabolism, are from a 16-week randomized, double-blind, placebo-controlled withdrawal period study involving children and adults aged four years and older. The study demonstrated that participants who transitioned to placebo experienced a significant worsening of hyperphagia compared to those who remained on VYKAT XR. These findings contributed to the U.S. FDA approval of VYKAT XR as the first and only treatment for hyperphagia in PWS. The results have been publicly presented through this peer-reviewed publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9619551) on January 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601818318?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601818318","market":"nz","top_or_hot":-1,"title":"Soleno Therapeutics Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced the publication of results from a pivotal clinical study evaluating VYKAT™ XR (diazoxide choline extended-release tablets) in the treatment of hyperphagia in individuals with Prader-Willi syndrome <a href=\"https://laohu8.com/S/PWS\">$(PWS)$</a>. The results, now published in the Journal of Clinical Endocrinology and Metabolism, are from a 16-week randomized, double-blind, placebo-controlled withdrawal period study involving children and adults aged four years and older. The study demonstrated that participants who transitioned to placebo experienced a significant worsening of hyperphagia compared to those who remained on VYKAT XR. These findings contributed to the U.S. FDA approval of VYKAT XR as the first and only treatment for hyperphagia in PWS. The results have been publicly presented through this peer-reviewed publication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9619551) on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soleno Therapeutics Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoleno Therapeutics Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-05 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced the publication of results from a pivotal clinical study evaluating VYKAT™ XR (diazoxide choline extended-release tablets) in the treatment of hyperphagia in individuals with Prader-Willi syndrome <a href=\"https://laohu8.com/S/PWS\">$(PWS)$</a>. The results, now published in the Journal of Clinical Endocrinology and Metabolism, are from a 16-week randomized, double-blind, placebo-controlled withdrawal period study involving children and adults aged four years and older. The study demonstrated that participants who transitioned to placebo experienced a significant worsening of hyperphagia compared to those who remained on VYKAT XR. These findings contributed to the U.S. FDA approval of VYKAT XR as the first and only treatment for hyperphagia in PWS. The results have been publicly presented through this peer-reviewed publication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9619551) on January 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL2tKWnq:1","article_id":"2601818318","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601818318","pubTimestamp":1767618118,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Soleno Therapeutics Inc. has announced the publication of results from a pivotal clinical study evaluating VYKAT XR  in the treatment of hyperphagia in individuals with Prader-Willi syndrome . The results, now published in the Journal of Clinical Endocrinology and Metabolism, are from a 16-week randomized, double-blind, placebo-controlled withdrawal period study involving children and adults aged four years and older. The study demonstrated that participants who transitioned to placebo experienced a significant worsening of hyperphagia compared to those who remained on VYKAT XR. These findings contributed to the U.S. FDA approval of VYKAT XR as the first and only treatment for hyperphagia in PWS. The results have been publicly presented through this peer-reviewed publication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","SLNO":"Soleno Therapeutics","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Soleno Therapeutics报告VYKAT XR治疗Prader-Willi综合征的3期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLNO":0.9,"NDAQ":0.9},"content_text":"Soleno Therapeutics Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome\n    \n\n        Soleno Therapeutics Inc. has announced the publication of results from a pivotal clinical study evaluating VYKAT™ XR (diazoxide choline extended-release tablets) in the treatment of hyperphagia in individuals with Prader-Willi syndrome $(PWS)$. The results, now published in the Journal of Clinical Endocrinology and Metabolism, are from a 16-week randomized, double-blind, placebo-controlled withdrawal period study involving children and adults aged four years and older. The study demonstrated that participants who transitioned to placebo experienced a significant worsening of hyperphagia compared to those who remained on VYKAT XR. These findings contributed to the U.S. FDA approval of VYKAT XR as the first and only treatment for hyperphagia in PWS. The results have been publicly presented through this peer-reviewed publication.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9619551) on January 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601818318","isCrawlerRequest":true}